UB Paderborn / Katalog / Suche / in CDI

Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient

Annals of oncology, 2018-01, Vol.29 (1), p.286-287

2018

Volltextzugriff (PDF)

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation

Annals of oncology, 2014-02, Vol.25 (2), p.404-408

2014

Volltextzugriff (PDF)

Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona

Annals of oncology, 2022-06, Vol.33 (6), p.661-663

2022

Volltextzugriff (PDF)

FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)

Annals of oncology, 2018-10, Vol.29, p.viii260-viii260

2018

Volltextzugriff (PDF)

Management of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence

Annals of oncology, 2018-10, Vol.29, p.viii523-viii523

2018

Volltextzugriff (PDF)

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT

Targeted oncology, 2014-06, Vol.9 (2), p.155-162

2014

Volltextzugriff (PDF)

6626 POSTER Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study

European journal of cancer (1990), 2011, Vol.47, p.S479-S480

2011

Volltextzugriff (PDF)

6608 POSTER Bax and p53 as Outcome Predictive in Metastatic Gastric Cancer (MGC) Patients Treated With First-Line COI (Capecitabine, Oxaliplatin, and Irinotecan) Regimen

European journal of cancer (1990), 2011, Vol.47, p.S474-S474

2011

Volltextzugriff (PDF)

6628 POSTER A Combination of RAD001 and Octreotide LAR as First-line Treatment of Well Differentiated Neuroendocrine Tumours – an I.T.M.O. (Italian Trials in Medical Oncology) Group Study

European journal of cancer (1990), 2011, Vol.47, p.S480-S480

2011

Volltextzugriff (PDF)

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients

Clinical & translational oncology, 2013-07, Vol.15 (7), p.582-586

2013

Volltextzugriff (PDF)

Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience

European journal of cancer (1990), 2022-11, Vol.175, p.S38-S39

2022

Volltextzugriff (PDF)

P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S467-S467

2018

Volltextzugriff (PDF)

144PD Leptomeningeal metastases in EGFR-mutated non-small cell lung carcinoma: Management after tyrosine kinase inhibitors

Journal of thoracic oncology, 2018-04, Vol.13 (4), p.S85-S86

2018

Volltextzugriff (PDF)

The influence of maternal passive and light active smoking on intrauterine growth and body composition of the newborn

European journal of clinical nutrition, 1998-10, Vol.52 (10), p.760-763

1998

Volltextzugriff (PDF)

Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer: A Phase II Study

American journal of clinical oncology, 2014-12, Vol.37 (6), p.545-549

2014

Volltextzugriff (PDF)

Crizotinib in Patients with Lung Cancer and Ros1 Fusion: Results from the European Cohort Euros1

Annals of oncology, 2014-09, Vol.25, p.iv457

2014

Volltextzugriff (PDF)

Prognostic Role of ERCC1, Bax and TP53 in Advanced Colorectal Cancer (CRC) PTS Randomly Assigned to First-Line UFT/Leucovorin (LV) Plus Irinotecan (Tegafiri) Versus UFT/LV Plus Oxaliplatin (Tegafox)

Annals of oncology, 2012-09, Vol.23, p.ix212

2012

Volltextzugriff (PDF)

628 - Prognostic Role of ERCC1, Bax and TP53 in Advanced Colorectal Cancer (CRC) PTS Randomly Assigned to First-Line UFT/Leucovorin (LV) Plus Irinotecan (Tegafiri) Versus UFT/LV Plus Oxaliplatin (Tegafox)

Annals of oncology, 2012-09, Vol.23, p.ix212-ix212

2012

Volltextzugriff (PDF)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib

Pharmacogenomics and personalized medicine, 2014-01, Vol.7 (default), p.107-116

2014

Volltextzugriff (PDF)

P035 Sequential targeted therapy with sunitinib-sorafenib (SU-SO) versus sorafenib-sunitinib (SO-SU) in metastatic renal cell carcinoma: Results from a large cohort of patients

European urology supplements : official journal of the European Association of Urology, 2013-11, Vol.12 (6), p.142-142

2013

Volltextzugriff (PDF)

1446PManagement of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

761PFOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Leptomeningeal metastases in EGFR-mutated non-small cell lung carcinoma: Management after tyrosine kinase inhibitors: 144PD

Journal of thoracic oncology, 2018-04, Vol.13 (4 Suppl), p.S85-S86

2018

Volltextzugriff (PDF)

1298PCRIZOTINIB IN PATIENTS WITH LUNG CANCER AND ROS1 FUSION: RESULTS FROM THE EUROPEAN COHORT EUROS1

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv457-iv458

2014

Volltextzugriff (PDF)

Evoluzione storica del concetto di aggressività in psicoanalisi ed etologia

Acta medicae historiae Patavina, 1981, Vol.28, p.9

1981

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation

Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona

FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)

Management of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT

6626 POSTER Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study

6608 POSTER Bax and p53 as Outcome Predictive in Metastatic Gastric Cancer (MGC) Patients Treated With First-Line COI (Capecitabine, Oxaliplatin, and Irinotecan) Regimen

6628 POSTER A Combination of RAD001 and Octreotide LAR as First-line Treatment of Well Differentiated Neuroendocrine Tumours – an I.T.M.O. (Italian Trials in Medical Oncology) Group Study

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients

Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience

P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases

144PD Leptomeningeal metastases in EGFR-mutated non-small cell lung carcinoma: Management after tyrosine kinase inhibitors

The influence of maternal passive and light active smoking on intrauterine growth and body composition of the newborn

Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer: A Phase II Study

Crizotinib in Patients with Lung Cancer and Ros1 Fusion: Results from the European Cohort Euros1

Prognostic Role of ERCC1, Bax and TP53 in Advanced Colorectal Cancer (CRC) PTS Randomly Assigned to First-Line UFT/Leucovorin (LV) Plus Irinotecan (Tegafiri) Versus UFT/LV Plus Oxaliplatin (Tegafox)

628 - Prognostic Role of ERCC1, Bax and TP53 in Advanced Colorectal Cancer (CRC) PTS Randomly Assigned to First-Line UFT/Leucovorin (LV) Plus Irinotecan (Tegafiri) Versus UFT/LV Plus Oxaliplatin (Tegafox)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib

P035 Sequential targeted therapy with sunitinib-sorafenib (SU-SO) versus sorafenib-sunitinib (SO-SU) in metastatic renal cell carcinoma: Results from a large cohort of patients

1446PManagement of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence

761PFOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)

Leptomeningeal metastases in EGFR-mutated non-small cell lung carcinoma: Management after tyrosine kinase inhibitors: 144PD

1298PCRIZOTINIB IN PATIENTS WITH LUNG CANCER AND ROS1 FUSION: RESULTS FROM THE EUROPEAN COHORT EUROS1

Evoluzione storica del concetto di aggressività in psicoanalisi ed etologia

Suchergebnisse filtern